Previous 10 | Next 10 |
Study also shows DecisionDx-SCC is being appropriately utilized by clinicians treating patients with cutaneous squamous cell carcinoma and one or more risk factors, as evidenced by first-year clinical order data Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving he...
Linked data from Castle’s ongoing collaboration with the NCI to link testing data with data from the SEER Program’s registries showed that DecisionDx®-Melanoma can provide significant risk stratification and identify patients with a low risk of death who may potenti...
Castle Biosciences, Inc. ( NASDAQ: CSTL ), a cancer-focused diagnostics company, added ~8% on Tuesday after announcing new data supporting its TissueCypher test, which is designed to predict high-grade dysplasia (HGD) and/or esophageal cancer in patients with Barrettȁ...
Data presented at the 2022 American College of Gastroenterology (ACG 2022) Annual Scientific Meeting Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing that the use of TissueC...
Multiple poster presentations at the 2022 Fall Clinical Dermatology Conference share this and other data supporting Castle’s suite of tests for skin cancer Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient ...
Study data also show that using certain DecisionDx-Melanoma test results in conjunction with current guidelines can reduce the number of SLNB procedures performed, particularly in patients with a low biological risk of metastasis Castle Biosciences, Inc. (Nasdaq: CSTL), a co...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2022, after the close of market on Wednesday, Nov. 2, 20...
Data presented during the 30 th United European Gastroenterology (UEG) Week in Vienna, Austria Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from a randomized controlled tria...
Poster presentation given by Harold Rabinovitz, M.D., Professor of Dermatology at the Medical College of Georgia in Augusta, Georgia Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced ...
New data demonstrate the potential impact of DecisionDx®-SCC test results to guide risk-aligned patient management plans and increase confidence in disease management decisions Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests ...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...